The relevance of osteosarcoma as a model for a highly metastatic human cancer, along with preclinical data generated herein that supports the opportunity to evaluate mTOR inhibitors in canine osteosarcoma, paves the way for clinical evaluation of rapamycin and other mTOR inhibitors in tumor bearing dogs as part of an integrated and comparative drug development approach. This evidence concerns the gene MTOR and cancer.